Medication info
Amrovica HCT Tablets 10/40/12.5 Milligrams

Amrovica HCT Tablets 10/40/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
Grayish-red round film-coated tablet
Packaging
28 tablets (14 tablets/PTP *2)
Approval status
Active

MFDS item code 201805285 · Approved 2018.12.26 · Insurance code 653404260

Summary

Main use
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amount of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years and older) In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this medicine in older adults aged 75 years and older, monitoring should be particularly careful when administering this medicine.
Child dose
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy

  • Essential hypertension
View approved original text

Combination therapy of Amlodipine and Olmesartan Medoxomil is used when blood pressure is not adequately controlled in patients with essential hypertension. These medications work to dilate blood vessels and lower blood pressure, helping effectively manage hypertension. When blood pressure is uncontrolled, this combination therapy can reduce the risk of cardiovascular disease and maintain health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The amount of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg □ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). □ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. □ Older adults (65 years and older) In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this medicine in older adults aged 75 years and older, monitoring should be particularly careful when administering this medicine.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, therefore, it must be stopped immediately if pregnancy is confirmed. Those allergic to this medication or similar ingredients should not take it. It is safest not to use this medication in pregnant or nursing individuals, patients with severe hypotension, or those with severe heart, kidney, or liver impairment. Patients with reduced blood volume or those taking diuretics should be closely monitored for hypotension upon initial use of this medication. Patients with impaired kidney function, those who have undergone kidney transplants, patients with renal artery hypertension, and those with impaired liver function should use this medication with caution, and regular blood tests and kidney function checks are necessary. This medication lowers blood pressure, which may cause dizziness or drowsiness; caution is advised when engaging in activities such as working at heights or driving. While taking this medication, interactions with other medications may occur, particularly when taking lithium, non-steroidal anti-inflammatory drugs, or other antihypertensives, so it is advisable to consult a doctor or pharmacist. Nursing women should avoid taking this medication or consider stopping breastfeeding, as the ingredients may pass into breast milk. Use in children under 18 years of age is not recommended as the safety and efficacy of this medication have not been established. Elderly patients may have reduced kidney and liver function; it is recommended to start at a low dose and monitor their condition closely. In the event of an overdose, severe hypotension and cardiac arrhythmias may occur, and immediate medical attention is required. This medication should be stored away from direct sunlight and moisture, in a place inaccessible to children, and should not be transferred to another container for safety. Additionally, this medication may cause various side effects such as skin hypersensitivity reactions, photosensitivity, electrolyte imbalances, and liver function abnormalities in some patients, so any unusual symptoms should be reported to healthcare professionals immediately.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, appetite loss, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disturbances, dizziness, orthostatic dizziness, syncope, taste disturbance, hypertonicity, sensory decrease, paresthesia, peripheral neuropathy, drowsiness, syncope, convulsions, loss of appetite, tremors, visual disturbances, decreased tear production, myopia worsening, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic obstruction, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urinary dysfunction, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, ennui, edema, pain, facial swelling, elevated blood creatinine, elevated blood urea, elevated blood uric acid, decreased blood potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated blood creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture and should be stored in a tightly sealed container. It is best to keep the storage temperature between 1 and 30 degrees Celsius. This way, the efficacy of the medication can be well maintained and used safely.

Appearance and packaging

Appearance

Grayish-red round film-coated tablet

Package unit

28 tablets (14 tablets/PTP *2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.